4DMT Announces New Employment Inducement Grants
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on December 9, 2025 its compensation committee granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
The inducement plan was approved by the board in February 2025 and is being used pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to attract new hires.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed moves, with examples ranging from -3.04% (TECX) to +7.44% (OCGN), suggesting FDMT’s modest 0.83% gain was stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Conference presentation | Neutral | +3.5% | J.P. Morgan Healthcare Conference presentation and webcast availability announcement. |
| Nov 20 | Conference participation | Neutral | -4.3% | Evercore Healthcare Conference fireside chat and investor meetings disclosure. |
| Nov 17 | Executive appointment | Positive | +1.5% | Appointment of a new CFO to lead finance and strategic initiatives. |
| Nov 14 | Inducement grants | Neutral | +1.5% | RSU awards to new non-executive employees under inducement plan. |
| Nov 10 | Earnings and updates | Negative | -3.1% | Q3 2025 results with larger loss alongside cash and partnership updates. |
Across recent events, FDMT’s share moves have generally aligned with the nature of news, including conferences, management changes, equity compensation, and earnings.
This announcement adds another employment inducement grant under the 2025 plan, following a similar RSU grant on Nov 11, 2025. In recent months, FDMT reported Q3 2025 results with a larger loss, completed a significant equity offering, and secured an Otsuka collaboration with substantial upfront and milestone potential. The company has also highlighted upcoming conference presentations and strengthened its finance leadership with a new CFO, underscoring ongoing strategic and capital markets activity.
Market Pulse Summary
This announcement details a modest inducement grant of 13,800 RSUs to three new non-executive employees under the 2025 Employment Inducement Award Plan authorized under Nasdaq Rule 5635(c)(4). It follows a similar RSU grant in November, reflecting ongoing hiring as the company advances late-stage programs. Investors may track cumulative equity awards, recent equity financing activity, and upcoming clinical or partnership milestones when assessing overall dilution and execution risk.
Key Terms
restricted stock units (RSUs) financial
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 13,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
FAQ
What did 4D Molecular Therapeutics (FDMT) grant on December 9, 2025?
Under which plan were the FDMT RSUs granted on December 9, 2025?
When was FDMT’s 2025 Employment Inducement Award Plan approved?
Why did FDMT use Rule 5635(c)(4) for the December 9, 2025 grants?
How many employees received inducement RSUs from FDMT on December 9, 2025?
Do the December 9, 2025 RSU grants to FDMT employees indicate executive compensation changes?
